{"disease":{"id":"mild-to-moderate-dementia","name":"mild to moderate dementia"},"drugs":{"marketed":[{"drug_id":"galantamine","indication_name":"Mild to moderate dementia of the Alzheimer's type","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Razadyne","generic_name":"GALANTAMINE","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Acetylcholinesterase","drug_class":"Cholinesterase Inhibitor","quality_score":62,"revenue":null,"mechanism":"Razadyne works by blocking the enzyme that breaks down acetylcholine, allowing more of this neurotransmitter to be available in the brain."},{"drug_id":"galantamine-hydrobromide","indication_name":"Mild to moderate dementia of the Alzheimer's type","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"GALANTAMINE HYDROBROMIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":31,"revenue":null,"mechanism":null},{"drug_id":"benzgalantamine","indication_name":"mild to moderate dementia of the Alzheimer's type","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zunveyl","generic_name":"BENZGALANTAMINE","company_name":"Alpha Cognition","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":56,"revenue":null,"mechanism":"Zunveyl works by enhancing communication between brain cells, specifically by stimulating cholinergic receptors."}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01081743","title":"Effectiveness of Care Management in Alzheimer Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":270,"lead_sponsor_name":"Institut de Sante Publique, d'Epidemiologie et de Developpement","has_results":false},{"nct_id":"NCT05561998","title":"Talking Mats as Decision Aid for Older People Living With Mild to Moderate Dementia","phase":"NA","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Göteborg University","has_results":false},{"nct_id":"NCT03750409","title":"Assessing Feasibility of Prolonged Repetitive Near Infrared Light Stimulation in Early to Mid-Stage Dementia","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Baylor Research Institute","has_results":false},{"nct_id":"NCT03462121","title":"A Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":83,"lead_sponsor_name":"Regenera Pharma Ltd","has_results":false},{"nct_id":"NCT03890796","title":"Activity Scheduling for Older Adults With Dementia","phase":"NA","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"The Hong Kong Polytechnic University","has_results":false},{"nct_id":"NCT05844241","title":"The Effect of Auditory Interventions on Anxiety and Agitation in People With Dementia","phase":"NA","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Lucid, Inc.","has_results":false},{"nct_id":"NCT07033468","title":"The Feasibility and the Efficacy of the Full-immersive Virtual Reality Cognitive Training in Patients With Mild or Moderate Dementia","phase":"NA","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}